TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception

TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception
A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food and Drug Administration, An emergency IND can be used by physicians to request permission to give an investigational medication to a person with a life-threatening condition, provided no satisfactory alternative therapy is available. The treatment is being administered by Jacob Lalezari, MD, chief executive officer of Quest Clinical Research and an investigator in other leronlimab clinical trials, which are testing it as an anti-retroviral therapy for people with HIV. “This patient has a particularly aggressive type of mTNBC [metastatic TNBC],” Lalezari said in a press release. “I believe that leronlimab represents a new potentially therapeutic modality in mTNBC.” Leronlimab is a human antibody designed to block the CCR5 surface receptor protein, whose levels are increased in several cancers, including TNBC. Previous studies have shown that, by blo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.